Lumbricus rubellus extract - Dexa Medica
Alternative Names: Disolf; DLBS-1033; Lumbricus low molecular weight proteins; Red earthworm extractLatest Information Update: 18 Dec 2023
Price :
$50 *
At a glance
- Originator Dexa Medica
- Class Alternative medicine; Enzymes; Thrombolytics; Traditional Chinese medicine
- Mechanism of Action Fibrin inhibitors; Fibrinogen inhibitors; Fibrinolysis stimulants; Fibrinolytic agents; Janus kinase 1 inhibitors; Matrix metalloproteinase 9 inhibitors; NF-kappa B inhibitors; Platelet aggregation inhibitors; STAT1 transcription factor inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Stroke
- Phase II/III Acute coronary syndromes; Peripheral arterial disorders
Most Recent Events
- 12 Dec 2023 Dexa Medica terminates a phase II/III ADDLIST trial in Stroke in Indonesia (PO) (NCT02133521)
- 29 Sep 2020 Phase II/III is ongoing for Stroke (Adjunctive treatment) in Indonesia (NCT04425590)
- 01 Apr 2020 Dexa Laboratories Of Biomolecular Science initiates enrolment in a phase II/III trial in Stroke (Adjunctive treatment) in Indonesia (PO) (NCT04425590)